Related Experiment Video
Updated: Jan 29, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo
Yusuf A Haggag1,2, Kyle B Matchett3, Robert A Falconer4
1Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta 31111, Egypt. youssif.hagag@pharm.tanta.edu.eg.
Abstract:
The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1 (Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid) PEG-PLGA polymeric nanoparticles (NPs). A modified double emulsion solvent evaporation technique was used to optimise the physicochemical properties of these peptide-loaded biodegradable NPs. The anti-cancer activity of peptide-loaded NPs was studied in vitro using Ran-expressing metastatic breast (MDA-MB-231) and lung cancer (A549) cell lines, and in vivo using Solid Ehrlich Carcinoma-bearing mice. The anti-metastatic activity of peptide-loaded NPs was investigated using migration, invasion and colony formation assays in vitro. A PEG-PLGA-nanoparticle encapsulating N-terminal peptide showed a pronounced antitumor and anti-metastatic action in lung and breast cancer cells in vitro and caused a significant reduction of tumor volume and associated tumor growth inhibition of breast cancer model in vivo. These findings suggest that the novel inhibitory peptides encapsulated into PEGylated PLGA NPs are delivered effectively to interact and deactivate Ran. This novel Ran-targeting peptide construct shows significant potential for therapy of breast cancer and other cancers mediated by Ran overexpression.
Insights
Novel peptides targeting Ras protein-Regulator of chromosome condensation 1 (Ran) were encapsulated in nanoparticles for cancer therapy. These peptide-loaded nanoparticles demonstrated significant antitumor and anti-metastatic effects in breast and lung cancer models.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Effective delivery of anticancer agents to subcellular targets remains a challenge in cancer therapy.
- Peptides offer potential as selective, potent therapeutics with low toxicity to normal cells.
- Ras protein-Regulator of chromosome condensation 1 (Ran) is a novel therapeutic target in breast cancer.
Purpose of the Study:
- To develop and evaluate novel Ran-inhibitory peptides encapsulated in polyethylene glycol-poly (lactic-co-glycolic acid) (PEG-PLGA) nanoparticles for cancer treatment.
- To assess the anticancer and anti-metastatic efficacy of these peptide-loaded nanoparticles in vitro and in vivo.
Main Methods:
- A modified double emulsion solvent evaporation technique was used to create optimized peptide-loaded PEG-PLGA nanoparticles.
- In vitro studies utilized Ran-expressing breast (MDA-MB-231) and lung (A549) cancer cell lines.
- In vivo efficacy was evaluated in Solid Ehrlich Carcinoma-bearing mice, alongside migration, invasion, and colony formation assays.
Main Results:
- PEG-PLGA nanoparticles encapsulating an N-terminal peptide exhibited significant antitumor activity against breast and lung cancer cells in vitro.
- These nanoparticles demonstrated pronounced anti-metastatic effects in vitro.
- In vivo studies showed a significant reduction in tumor volume and growth inhibition in a breast cancer model.
Conclusions:
- Novel Ran-inhibitory peptides effectively delivered via PEG-PLGA nanoparticles show significant potential for cancer therapy.
- This Ran-targeting peptide construct demonstrates promise for treating breast cancer and other Ran-overexpressing cancers.
- The developed nanoparticles offer an effective strategy for delivering therapeutic peptides to cancer cells.
More Related Videos
Related Concept Videos
Peptide Bonds
Self-Efficacy
Equivalence: In Vitro and In Vivo Bioequivalence
Excitatory and Inhibitory Effects of Neurotransmitters
Impact Loading
In cases of elastic deformation,...
Drug Product Performance: In Vitro–In Vivo Correlation

